Genmab — December 2021
-
-
Ikke det store nytårsfyrværkeri for Genmab her i december. Det har overall været skuffende med kursen i år..men fint med nyhederne. Godt Nytår
-
2021 blev et stygt år for mange af aktierne i bioteksektoren. Et seriøst bud på årsagerne til dette kan læses i en artikel fra ProInvestors Nasdaq Newsfeed. https://www.proinvestor.com/index.php?p=debat_1&postid=99797
-
Med et "kurs-range" i løbet af 2021 fra 1900 til 3150, kan man næppe konkludere alverdens af kursen dags dato. Genmab som selskab, har leveret varen i 2021. 2022 bliver mindst lige så interessant som 2021 - og gerne bedre på kursen. Godt nytår til jer alle
-
Lidt mere opfølgning på Tec. https://www.biospace.com/article/backed-by-strong-survival-janssen-submits-bla-for-multiple-myeloma-drug/
-
God morgen og godt nytår.
-
Through timely company announcements,
media releases, events and presentations, Genmab discloses and informs all our stakeholders of key events throughout the year. https://www.proinvestor.com/investornyt/757315/december-31-2021-financial-calendar-year-end -
European Shares Slide On Covid Worries https://www.proinvestor.com/investornyt/757471/european-shares-slide-on-covid-worries
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind